Core Viewpoint - The healthcare sector is perceived as a safe investment during market volatility, with certain stocks presenting strong opportunities for investment with a modest amount of capital [1]. Group 1: AbbVie - AbbVie has seen a year-to-date share price increase of approximately 20% despite broader market concerns [2]. - The company’s product portfolio includes successful drugs for autoimmune diseases, such as Rinvoq and Skyrizi, as well as cancer treatments like Imbruvica and Venclexta [3]. - AbbVie’s acquisition of Allergan has positioned it as a leader in the aesthetics market, with popular products like Botox and Juvederm [3]. - The current share price of AbbVie is around $212, with a low PEG ratio of 0.45 based on five-year earnings growth projections, indicating strong growth potential [4]. - AbbVie offers a forward dividend yield of 3.09% and has a history of 53 consecutive years of dividend increases, qualifying it as a Dividend King [4]. Group 2: Vertex Pharmaceuticals - Vertex Pharmaceuticals has outperformed AbbVie with a share price increase of over 20% year-to-date [5]. - The company holds a near-monopoly in cystic fibrosis treatment, which enhances its market position [5]. - Recent FDA approvals for Vertex’s new CF drug Alyftrek and non-opioid pain medication Journavx are expected to drive significant growth [6][7]. - The share price of Vertex is just under $500, providing an opportunity to invest in its promising pipeline, including a potential cure for severe type 1 diabetes [8]. Group 3: Kiniksa Pharmaceuticals - Kiniksa Pharmaceuticals is currently not profitable but has shown strong market performance with double-digit gains this year [9]. - The company’s drug Arcalyst, approved for recurrent pericarditis, saw a 79% year-over-year sales increase in 2024, reaching $417 million, with projections of up to $580 million for the current year [10]. - Kiniksa has only captured about 13% of the market for Arcalyst, indicating significant growth potential as it expands its market share [10]. - The share price of Kiniksa is around $22, allowing for investment alongside AbbVie and Vertex [11].

I publish my best ideas and top coverage on the Growth Stock Forum . If you're interested in finding great growth stocks, with a focus on biotech, consider signing up. We focus on attractive risk/reward situations and track each of our portfolio and watchlist stocks closely. To receive e-mail notifications for my public articles and blogs, please click the follow button . And to go deeper, sign up to Growth Stock Forum.AbbVie Inc. (NYSE: ABBV ) entered the obesity race last week when it in-licensed GUB01429 ...

Market Overview - The market is currently experiencing significant uncertainty, with the S&P 500 down 8.6% and the Nasdaq down 13.4% from recent highs [2] - Artificial intelligence stocks, such as Nvidia, have also seen declines, with Nvidia approximately 14% off its year-to-date high [3] Investment Strategies - To protect capital during market downturns, investors are advised to consider stable dividend stocks that offer reliable income and lower volatility compared to high-growth tech stocks [3] Real Estate Investment Trusts (REITs) - REITs are attractive for income-focused investors due to their requirement to distribute 90% of taxable income to shareholders, resulting in higher yields [4] - Vici Properties owns "trophy properties" that are difficult to replace, including major Las Vegas casino resorts and an entertainment complex in New York, which positions it favorably in the market [5] - Vici Properties collected 100% of its rents during the COVID-19 pandemic and has consistently increased its dividend since inception, indicating strong financial health [6][7] Pharmaceutical Sector - AbbVie has transitioned from reliance on its blockbuster drug Humira to a more diversified portfolio following its acquisition of Allergan, which added products like Botox and Juvederm [10] - Despite a decline in Humira sales from over $21 billion in 2022 to $9 billion in 2024 due to competition from biosimilars, AbbVie is expected to see significant growth from new anti-inflammatory drugs, projected to generate $27 billion in sales by 2027 [9][11] - AbbVie has maintained a growing dividend since its spinoff from Abbott Laboratories in 2013, currently paying $1.64 quarterly, providing a forward yield of 3% [11] Conclusion - Vici Properties and AbbVie are highlighted as strong investment options for generating steady, growing dividends regardless of market conditions, making them suitable for long-term holding [12]

It's not too often that pharmaceutical drugs become household names, but that's happening with medicines in the weight loss market. Brands such as Wegovy and Zepbound -- the leading anti-obesity therapies -- are now well known and are generating billions of dollars in annual sales. That's why other drugmakers want to dip their toes in this lucrative and high-growth market.AbbVie (ABBV 1.68%) is one of them. The company, best known for its work in immunology, recently made a move to enter the weight loss spa ...

Core Insights - The average tax refund in 2024 is $3,138, similar to the previous year's average of $3,167, providing potential extra cash for investments [1] Group 1: AbbVie - AbbVie is a leading healthcare company with a market capitalization of approximately $370 billion and offers a dividend yield of 3.1%, significantly higher than the S&P 500 average of 1.3% [3][6] - Concerns about AbbVie losing patent protection for its top-selling drug Humira are mitigated by the success of its newer immunology drugs, Skyrizi and Rinvoq, which generated $17.7 billion in revenue last year, while Humira's sales fell by 38% to just under $9 billion [4] - AbbVie's diverse business includes treatments in immunology, oncology, neuroscience, and aesthetics, with potential growth in the aesthetics sector driven by rising popularity of GLP-1 weight loss treatments and Botox [5] Group 2: Alibaba Group - Alibaba has gained traction among growth investors, with its stock rising over 60% in the past six months, bolstered by the launch of its AI chatbot Qwen 2.5-Max, which reportedly outperforms ChatGPT-4o [7][8] - Despite a modest sales growth of 8% in the last quarter of 2024, reaching $38.4 billion, the partnership with Apple for AI features signals promising future growth [8][9] - The stock is trading at 13 times expected future profits, presenting a potentially attractive investment opportunity, alongside a dividend yield of 1.5% [9] Group 3: FedEx - FedEx, a key player in shipping and logistics, offers a dividend yield of 2.1% and is well-positioned to benefit from the growing e-commerce market, projected to expand at an annual rate of around 19% through the end of the decade [10] - Recent challenges include a 1% decline in sales over the past two quarters and a 23% drop in operating income, but the company is focusing on efficiency improvements and AI investments to enhance profitability [11][12] - With a forward price-to-earnings ratio of just 12, FedEx is considered a potentially undervalued investment for long-term holders [12]

Core Viewpoint - AbbVie is expanding its presence in the obesity treatment market by in-licensing GUB014295, a long-acting amylin analog, from Gubra, with a total potential deal value of $2.225 billion [1][2][3] Industry Overview - The obesity market is projected to reach $100 billion by 2030, with current dominance by GLP-1 drugs from Eli Lilly and Novo Nordisk [3] - Major pharmaceutical companies, including Merck, Pfizer, Amgen, and AstraZeneca, are actively pursuing opportunities in the obesity space through in-house development or licensing deals [3] AbbVie's Product Performance - AbbVie has successfully launched Skyrizi and Rinvoq, generating combined sales of $17.7 billion in 2024, particularly excelling in the inflammatory bowel disease market [5][6] - The company anticipates combined sales of Skyrizi and Rinvoq to exceed $31 billion by 2027, driven by market growth and new indications [7] Pipeline and Acquisitions - AbbVie has a robust pipeline with several early/mid-stage candidates and expects multiple regulatory submissions and approvals in the next 12 months [8][9] - The company has been active in acquisitions, signing over 20 early-stage deals in 2024 to enhance its pipeline in immunology, oncology, and neuroscience [11][12] Sales Trends and Challenges - AbbVie is experiencing declining sales from Humira due to biosimilar competition, with a sharper decline expected in 2025 [13] - The aesthetics portfolio, including Juvederm fillers, has also seen a decline, with a 14.6% drop in sales in 2024 [14][15] Stock Performance and Valuation - AbbVie stock has outperformed the industry with a 14.8% increase over the past year [16][18] - The stock trades at a price/earnings ratio of 16.52, slightly below the industry average of 17.80, but higher than many large drugmakers [19][20] Earnings Estimates - The Zacks Consensus Estimate for AbbVie's 2025 earnings has increased from $12.24 to $12.29 per share, indicating positive sentiment [22]

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news straight to your inbox. Subscribe here to receive future editions.The booming weight loss drug market has gained a new potential competitor. AbbVie said on Monday that it will pay up to $2.2 billion to develop Danish drugmaker Gubra's experimental obesity drug, marking its late foray into the segment. Under the terms of the deal, the pharmaceutical giant will pay Gubra $350 million upfront ...

NORTH CHICAGO, Ill., March 4, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025. Management will participate in a fireside chat at 7:40 a.m. Central time.A live audio webcast of the presentation will be accessible through AbbVie's Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day.About AbbVieAbbVie's mission is to discover and deliver innovative medici ...

On Monday, AbbVie Inc ABBV and Gubra A/S announced a license agreement to develop GUB014295, a long-acting amylin analog for obesity. GUB014295 is currently in a Phase 1 clinical trial.“Our partnership with Gubra marks our entry into the obesity field, offering a compelling opportunity based on the potential to address patient needs while also fostering long-term growth for our company,” said Robert Michael, CEO of AbbVie.Also Read: Is Big Pharma About To Win? Goldman Sachs Weighs In On 340B And Medicaid Sh ...

Core Insights - AbbVie and Gubra A/S have entered into a license agreement to develop GUB014295, a long-acting amylin analog aimed at treating obesity, marking AbbVie's entry into the obesity treatment market [1][2][3] - GUB014295 is currently in Phase 1 clinical trials and is designed to activate amylin and calcitonin receptors, which may help suppress appetite and reduce food intake [2][3] - The agreement includes an upfront payment of $350 million to Gubra, with potential milestone payments totaling up to $1.875 billion, along with tiered royalties on global net sales [3] Company Overview - AbbVie is focused on innovative medicines addressing significant health issues, with a mission to transform patient care in areas of unmet need [2][8] - Gubra specializes in preclinical contract research services and peptide-based drug discovery, particularly in metabolic and fibrotic diseases, and reported revenue of DKK 266 million in 2024 [9] Clinical Development - The Phase 1 clinical trial of GUB014295 consists of two parts: Part 1 has been completed, while Part 2 is ongoing, involving a randomized, placebo-controlled design [6][7]